TIDMFIPP
Frontier IP Group plc
10 January 2020
RNS Reach
AIM: FIPP
10 January 2020
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - Exscientia enters collaboration with Bayer AG
to leverage the potential of Artificial Intelligence ("AI") in
cardiovascular and oncology drug discovery
Frontier IP, a specialist in commercialising university
intellectual property, is pleased to note that portfolio company
Exscientia ("Exscientia" or the "Company"), a world leader in
AI-driven drug discovery, that it has entered into a collaboration
with Bayer AG focused on cardiovascular disease and oncology.
Under the terms of the agreement, Exscientia may be eligible to
receive up to EUR240 million including upfront and research
payments, and for meeting near term and clinical milestones. The
Company may also receive sales royalties.
Exscientia's other partnerships include collaborations with
Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec.
Frontier IP currently holds a 3.25 per cent stake in the
Company.
Exscientia statement in full:
BAYER AND EXSCIENTIA COLLABORATE TO LEVERAGE THE POTENTIAL OF
ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR AND ONCOLOGY DRUG
DISCOVERY
Exscientia, the leading Artificial Intelligence (AI)-driven drug
discovery company, announced today that it has entered a
collaboration with Bayer AG that aims to accelerate the discovery
of small molecule drugs focused on cardiovascular disease and
oncology.
Under terms of the agreement, Exscientia will initially work on
three projects with targets agreed between both parties. Exscientia
may be eligible to receive up to EUR240 Million, including upfront
and research payments, near term and clinical milestones. As part
of the agreement, Exscientia may also receive sales royalties.
Professor Andrew Hopkins, CEO of Exscientia, commented: "We're
delighted to collaborate with Bayer, a globally recognised
pharmaceutical company. Since our pioneering Nature papers
demonstrating the automated design of small-molecules, we have
enhanced our platform and exemplified it commercially, by
accelerating the discovery of future drug molecules with
partners."
Dr. Joerg Moeller, Member of the Executive Committee of Bayer
AG's Pharmaceuticals Division and Head of Research and Development
added,
"We are driving forward digital transformation in R&D as we
believe that digital technologies such as AI can simplify and speed
up the discovery and development of new drugs for patients. The
collaboration with Exscientia is expected to help us to achieve
project milestones earlier and at the same time accelerate
timelines by enabling more precise identification of suitable drug
targets and lead structures."
As part of this collaboration, Exscientia will apply its Centaur
Chemist(TM) Artificial Intelligence (AI) drug discovery platform to
go beyond conventional human endeavour by using its evolutionary
computing and deep learning algorithms to discover and optimise
novel drug candidates at unprecedented productivity.
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 7332 2338
Neil Crabb, Chief Executive
Andrew Johnson, Communications & Investor M: 07464 546 025
Relations
www.frontierip.co.uk
Allenby Capital Limited (Nominated T: 0203 328 5656
Adviser)
Nick Athanas / Nicholas Chambers
Exscientia Limited contact@exscientia.co.uk
Mark Swindells, Chief Commercial Officer
www.exscientia.co.uk
www.twitter.com/exscientialtd
Edelman exscientia@edelman.com
Marianne Fekene +44(0) 7810298448
Camille Oster +44(0) 7812660934
NOTES FOR EDITORS
About Exscientia
Exscientia is at the forefront of Artificial Intelligence
(AI)-driven drug discovery and design. By fusing the power of AI
with the discovery experience of seasoned drug hunters, Exscientia
is the first company to automate drug design, surpassing
conventional approaches.
Exscientia's innovative Centaur Chemist(TM) platform enables
breakthrough productivity gains as well as new approaches to
improve drug efficacy. Novel compounds are automatically designed
and prioritised for synthesis by its AI systems, which rapidly
evolve compounds towards the desired candidate criteria for
clinical development.
Exscientia systems learn from both existing data resources and
experimental data from each design cycle. The principle is similar
to how a human would learn, but the AI process is far more
effective at identifying and assimilating multiple subtle and
complex trends to balance potency, selectivity and pharmacokinetic
criteria.
As a result, the AI-driven process is more likely to achieve the
end goal and to do this more rapidly and efficiently than
traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical
and life sciences companies, has its headquarters in Oxford, UK
with further offices in the UK, USA and Japan. For more information
visit us on www.exscientia.ai or follow us on Twitter
@exscientialtd.
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute media only /
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKKCBNKBKBCDK
(END) Dow Jones Newswires
January 10, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Frontier Ip (LSE:FIPP)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Frontier Ip (LSE:FIPP)
Storico
Da Mar 2023 a Mar 2024